Compare ARVN & MCFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARVN | MCFT |
|---|---|---|
| Founded | 2015 | 1968 |
| Country | United States | United States |
| Employees | N/A | 700 |
| Industry | Biotechnology: Pharmaceutical Preparations | Marine Transportation |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 658.2M | 604.0M |
| IPO Year | 2018 | 2015 |
| Metric | ARVN | MCFT |
|---|---|---|
| Price | $8.04 | $25.57 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 19 | 5 |
| Target Price | $15.05 | ★ $24.25 |
| AVG Volume (30 Days) | ★ 680.3K | 117.2K |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.84 | N/A |
| EPS | N/A | ★ 0.33 |
| Revenue | $262,600,000.00 | ★ $284,203,000.00 |
| Revenue This Year | N/A | $9.18 |
| Revenue Next Year | N/A | $8.23 |
| P/E Ratio | ★ N/A | $75.56 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.06 | $17.19 |
| 52 Week High | $14.22 | $28.44 |
| Indicator | ARVN | MCFT |
|---|---|---|
| Relative Strength Index (RSI) | 46.65 | 65.68 |
| Support Level | $7.35 | $21.90 |
| Resistance Level | $10.18 | $26.49 |
| Average True Range (ATR) | 0.41 | 0.93 |
| MACD | 0.17 | 0.30 |
| Stochastic Oscillator | 70.20 | 97.32 |
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
MasterCraft Boat Holdings Inc designs, manufactures, and markets performance sport boats and outboard boats. The company is based in the United States and operates in three brand-specific segments. The MasterCraft segment generates the majority of the company's revenue and includes inboard boats for water skiing, wakeboarding, and wake surfing. The Pontoon segment produces pontoon boats at its Owosso, Michigan facility. Pontoon boats are used for general recreational boating. The Aviara segment produces luxury day boats at its Merritt Island, Florida facility. Aviara boats are used for general recreational boating.